Balkrishan (Simba) Gill has joined the board of the UK specialty biopharmaceutical company PuriCore Plc to help it advance its proprietary immunomodulatory technology. Dr Gill is a serial entrepreneur and currently chief executive of Evelo Biosciences, a recently created developer of microbiome-based therapies which is located in Cambridge, Massachusetts, US.
Dr Gill has an MBA from INSEAD in France and completed his PhD at King’s College London with a focus on developing humanised antibodies to treat cancer.
PuriCore announced the appointment on 1 March 2016.
Copyright 2016 Evernow Publishing Ltd